This site is only intended for healthcare professionals in Belgium and Luxembourg.

Reblozyl® (luspatercept) has received European Medicines Agency approval. The registration status and approved product labels of Reblozyl may vary from country to country.

IMPORTANT: The information on this website is based on the EU Summary of Product Characteristics (SmPC). View the SmPC: in English, in French, in Dutch.

The information provided on this website is intended for use by a healthcare professional qualified to prescribe and supply medications, thus requiring specific scientific knowledge and training to interpret it correctly.

Please authenticate as a qualified healthcare professional.

Or

Alternatively, sign up for emails and access.

If you have any other queries, please contact us via email at medicalaffairs.belgium@bms.com.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See Section 4.8 in the EU Summary of Product Characteristics for more information. Before prescribing Reblozyl, please refer to the SmPC.

For your adult patients with
MDS- or β-thalassemia–associated anemia

With Reblozyl—the first and only erythroid maturation agent—you can reduce or even eliminate patients’ red blood cell (RBC) transfusion dependence.1-3

Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Before prescribing Reblozyl, please refer to the SmPC. View the EU SmPC in English, SmPC in French, SmPC in Dutch.

References:

1. Reblozyl® (luspatercept) [summary of product characteristics]. Celgene Europe BV, Utrecht.

2. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414.

3. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770.

You are now leaving this Celgene (a Bristol Myers Squibb Company) website for another external website.

Bristol Myers Squibb has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this website.

Proceed

Visit the site for HCPs in:

 Austria EU Netherlands U.S.A